Bio-Rad Laboratories, Inc. (BIO)Healthcare | Medical Devices | Hercules, United States | NYSE
311.00 USD
+7.66
(2.525%)
⇧
(April 21, 2026, 10:28 a.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:57 p.m. EDT
Bio-Rad is in a technical inflection zone where the $295-299 price level has built significant near-term bullish conviction, evidenced by heavy call optometry at the $300 strike. However, the fundamental data contradicts the short-term momentum; the stock trades at a sky-high forward P/E of 26.3x despite only 3.9% revenue growth and poor ROA (1.67%), while yield data confirms it pays no dividend. The market is pricing in a recovery, but the valuation gap between the 10.7x trailing P/E and 26.3x forward P/E suggests the 'hold' consensus is correct; this is a short-term momentum play, not a long-term value opportunity. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.064357 |
| MSTL | 0.064435 |
| AutoTheta | 0.070559 |
| AutoARIMA | 0.106257 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 75% |
| H-stat | 1.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.206 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.579 |
| Revenue per Share | 94.689 |
| Market Cap | 8,397,742,592 |
| Trailing P/E | 11.17 |
| Forward P/E | 27.41 |
| Beta | 1.16 |
| Profit Margins | 29.42% |
| Website | https://www.bio-rad.com |
As of April 18, 2026, 11:57 p.m. EDT: Options flow indicates a bullish bias near-term with very high call volume (156 units) and Open Interest (220 contracts) concentrated at the $300 strike, creating a strong floor barrier. The upcoming April 17th expiration shows overwhelming positioning in OTM calls (96% of OI). While there is some protective put activity (40 vol at $210 June), call gamma exposure is positive above $270. The abbreviated put data for June 210 notes new flow with volume exceeding open interest, but the dominant signal remains directional long positioning targeting the $300 psychological level.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.23822355 |
| Address1 | 1,000 Alfred Nobel Drive |
| All Time High | 832.7 |
| All Time Low | 0.851852 |
| Ask | 314.37 |
| Ask Size | 80 |
| Audit Risk | 4 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 244,610 |
| Average Daily Volume3 Month | 293,760 |
| Average Volume | 293,760 |
| Average Volume10Days | 244,610 |
| Beta | 1.158 |
| Bid | 309.7 |
| Bid Size | 40 |
| Board Risk | 9 |
| Book Value | 276.158 |
| City | Hercules |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 311.0 |
| Current Ratio | 5.621 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 312.85 |
| Day Low | 305.535 |
| Debt To Equity | 18.579 |
| Display Name | Bio-Rad Laboratories |
| Earnings Call Timestamp End | 1,777,582,800 |
| Earnings Call Timestamp Start | 1,777,582,800 |
| Earnings Timestamp | 1,777,579,200 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | 431,600,000 |
| Ebitda Margins | 0.16708 |
| Enterprise To Ebitda | 18.608 |
| Enterprise To Revenue | 3.109 |
| Enterprise Value | 8,031,366,144 |
| Eps Current Year | 10.2603 |
| Eps Forward | 11.34804 |
| Eps Trailing Twelve Months | 27.85 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 510 741 5817 |
| Fifty Day Average | 277.1618 |
| Fifty Day Average Change | 33.838196 |
| Fifty Day Average Change Percent | 0.12208824 |
| Fifty Two Week Change Percent | 23.822355 |
| Fifty Two Week High | 343.12 |
| Fifty Two Week High Change | -32.119995 |
| Fifty Two Week High Change Percent | -0.09361155 |
| Fifty Two Week Low | 211.43 |
| Fifty Two Week Low Change | 99.57001 |
| Fifty Two Week Low Change Percent | 0.47093606 |
| Fifty Two Week Range | 211.43 - 343.12 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 320,509,800,000 |
| Float Shares | 21,134,288 |
| Forward Eps | 11.34804 |
| Forward P E | 27.405615 |
| Free Cashflow | 256,550,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 7,450 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.52013 |
| Gross Profits | 1,343,600,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16203 |
| Held Percent Institutions | 0.91441 |
| Implied Shares Outstanding | 27,002,387 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,015,545,600 |
| Last Split Factor | 2:1 |
| Long Business Summary | Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. |
| Long Name | Bio-Rad Laboratories, Inc. |
| Market | us_market |
| Market Cap | 8,397,742,592 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_255743 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 759,900,032 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,060,160,426 |
| Number Of Analyst Opinions | 4 |
| Open | 305.05 |
| Operating Cashflow | 532,200,000 |
| Operating Margins | 0.088719994 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.01 |
| Phone | 510 724 7000 |
| Previous Close | 303.34 |
| Price Eps Current Year | 30.311005 |
| Price Hint | 2 |
| Price To Book | 1.1261669 |
| Price To Sales Trailing12 Months | 3.250907 |
| Profit Margins | 0.29417 |
| Quick Ratio | 3.894 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 7.6600037 |
| Regular Market Change Percent | 2.5252204 |
| Regular Market Day High | 312.85 |
| Regular Market Day Low | 305.535 |
| Regular Market Day Range | 305.535 - 312.85 |
| Regular Market Open | 305.05 |
| Regular Market Previous Close | 303.34 |
| Regular Market Price | 311.0 |
| Regular Market Time | 1,776,781,717 |
| Regular Market Volume | 17,268 |
| Return On Assets | 0.01669 |
| Return On Equity | 0.108380005 |
| Revenue Growth | 0.039 |
| Revenue Per Share | 94.689 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 21,924,404 |
| Shares Percent Shares Out | 0.0 |
| Shares Short | 26 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 947,436 |
| Short Name | Bio-Rad Laboratories, Inc. |
| Short Percent Of Float | 0.0 |
| Short Ratio | 0.0 |
| Source Interval | 15 |
| State | CA |
| Symbol | BIO |
| Target High Price | 320.0 |
| Target Low Price | 280.0 |
| Target Mean Price | 302.5 |
| Target Median Price | 305.0 |
| Total Cash | 1,540,700,032 |
| Total Cash Per Share | 57.083 |
| Total Debt | 1,384,800,000 |
| Total Revenue | 2,583,200,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 27.85 |
| Trailing P E | 11.1669655 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 290.89264 |
| Two Hundred Day Average Change | 20.10736 |
| Two Hundred Day Average Change Percent | 0.06912296 |
| Type Disp | Equity |
| Volume | 17,268 |
| Website | https://www.bio-rad.com |
| Zip | 94,547 |